




Searching News Database: Sigma-Tau
HSMN NewsFeed - 31 Aug 2017
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
HSMN NewsFeed - 21 Oct 2013
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
HSMN NewsFeed - 29 Apr 2013
Dave Lemus Promoted to Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
Dave Lemus Promoted to Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc.
HSMN NewsFeed - 29 Oct 2012
Sigma-Tau Pharmaceuticals, Inc. Announces Appointment of New Vice President of Commercial Operations
Sigma-Tau Pharmaceuticals, Inc. Announces Appointment of New Vice President of Commercial Operations
HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
HSMN NewsFeed - 18 Jan 2008
Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
HSMN NewsFeed - 22 Jun 2007
FDA Approves Carnitor(R) SF (Levocarnitine) Sugar-Free Oral Solution For Patients With Carnitine Deficiency
FDA Approves Carnitor(R) SF (Levocarnitine) Sugar-Free Oral Solution For Patients With Carnitine Deficiency
HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
HSMN NewsFeed - 25 May 2006
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial
Additional items found! 15

Members Archive contains
15 additional stories matching:
Sigma-Tau
(Password required)
Sigma-Tau
(Password required)